It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Non-classical monocyte subsets may derive from classical monocyte differentiation and the proportion of each subset is tightly controlled. Deregulation of this repartition is observed in diverse human diseases, including chronic myelomonocytic leukemia (CMML) in which non-classical monocyte numbers are significantly decreased relative to healthy controls. Here, we identify a down-regulation of hsa-miR-150 through methylation of a lineage-specific promoter in CMML monocytes. Mir150 knock-out mice demonstrate a cell-autonomous defect in non-classical monocytes. Our pulldown experiments point to Ten-Eleven-Translocation-3 (TET3) mRNA as a hsa-miR-150 target in classical human monocytes. We show that Tet3 knockout mice generate an increased number of non-classical monocytes. Our results identify the miR-150/TET3 axis as being involved in the generation of non-classical monocytes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 INSERM U1170, Gustave Roussy Cancer Center, Villejuif, France
2 INSERM U1170, Gustave Roussy Cancer Center, Villejuif, France; Université Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, France
3 INSERM US23, CNRS UMS 3655, Gustave Roussy Cancer Center, Villejuif, France
4 INSERM U1170, Gustave Roussy Cancer Center, Villejuif, France; Laboratoire d’Hématologie, Centre Hospitalier Régional Universitaire, Brest, France
5 INSERM U1170, Gustave Roussy Cancer Center, Villejuif, France; Laboratoire d’Hématologie, Centre Hospitalier Régional Universitaire, Nantes, France
6 INSERM U1170, Gustave Roussy Cancer Center, Villejuif, France; Département d’Hématologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
7 Département d’Immuno-Hématologie, Institut Cochin, Paris, France
8 INSERM U1170, Gustave Roussy Cancer Center, Villejuif, France; Université Paris Diderot, Paris, France; Département d’Hématologie, Gustave Roussy Cancer Center, Villejuif, France
9 Département d’Hématologie et d’Immunologie Biologiques, Hôpital Henri-Mondor, Créteil, France
10 INSERM U1170, Gustave Roussy Cancer Center, Villejuif, France; Université Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM US23, CNRS UMS 3655, Gustave Roussy Cancer Center, Villejuif, France
11 INSERM U1170, Gustave Roussy Cancer Center, Villejuif, France; Université Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, France; Département d’Hématologie, Gustave Roussy Cancer Center, Villejuif, France